Message #24 From:
NewsBot Date: January 8, 2007 09:44:00 AM
EGEI News eGene and Fisher Scientific Company Enter into Distribution Relationship in Canada
IRVINE, Calif.--(BUSINESS WIRE)--eGene Inc. (OTCBB:EGEI),
developer of a revolutionary high-performance genetic analysis
technology, announced today that it has entered into a distribution
agreement with Fisher Scientific, Canada to promote and sell eGene's
HDA-GT12 system in Canada.
David Molnar, Director of Sales at eGene, noted: "We are very pleased to
have Fisher Scientific as our distributor in Canada. Both companies have
seen exciting business opportunities for our genetic analyzer's use in
the area Fisher Scientific, Canada, serves, and eGene believes that
Fisher Scientific's expertise in marketing, technical support and
instrument service will suit our products very well. eGene will also
attend the Fisher Scientific National Sales Meeting in Vancouver, Canada
from January 16-18, 2007."
About Fisher Scientific Company
Fisher Scientific, Canada, is a division of Thermo Fisher Scientific
(NYSE:TMO), a world leader in providing customers with analytical
instruments, equipment, reagents and consumables, software and services
for research, analysis, discovery and diagnostics. With annual sales of
more than $9 billion, Thermo Fisher Scientific has 30,000 employees and
serves more than 350,000 customers in pharmaceutical and biotech
companies, hospitals and clinical diagnostic labs, universities,
research institutions and government agencies as well as environmental
and industrial quality control labs.
About eGene Inc.
eGene Inc. (www.egeneinc.com)
focuses its core technologies of capillary electrophoresis,
microfluidics, liquid handling and automation to develop and manufacture
low-cost microfluidic, miniaturized digital genetic analyzer systems,
software and consumables for biological materials testing applications.
These products detect, quantify, identify and characterize DNA and RNA
at high rates of specificity and sensitivity while automating routine
and non-routine laboratory and industrial procedures critical to product
safety, development quality and productivity.
This press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Such statements are made based on
management's current expectations and beliefs. Actual results may vary
from those currently anticipated based upon a number of factors. The
company undertakes no obligation to release publicly any revision, which
may be made to reflect events or circumstances after the date hereof.
